CTOs on the Move

ABS Global

www.absglobal.com

 
Headquartered in DeForest, Wisconsin, ABS Global is the world-leading provider of bovine genetics, reproduction`services, technologies and uddercare products.
  • Number of Employees: 250-1000
  • Annual Revenue: $50-100 Million

Executives

Name Title Contact Details

Similar Companies

AmnioLife

AmnioLife Corporation is a biotechnology company focused on the development and commercialization of a unique biologic suite of products designed to address unmet and underserved market needs with applications across multiple surgical specialties. We are committed to the development of novel biotechnology and regenerative therapeutics, primarily derived from placental origin. Currently we have filed a US provisional patent application on our core technology, ProLifixTM, an acellular collagen matrix. The Company has over 60 years of experience in biologics manufacturing and comercializaiton, and is led by Chris Broderick who recently launched a neurological tissue transplant technology and was responsible for over $10M in trending global sales.

Celsis Inc

Celsis Inc is a Chicago, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Totus Medicines

Founded in 2019, Totus Medicines uses revolutionary chemical biology to create life-changing therapies to treat previously untreatable diseases across the entire human genome. Totus is based in Cambridge, Massachusetts.

Strata Oncology

Strata Oncology, Inc. is a precision oncology company dedicated to delivering the best possible treatment for each patient with cancer. The company combines molecular profiling, real-world data, and a large-scale clinical trial platform to identify and deliver optimal treatments for patients with cancer.

Centre for Commercialization of Regenerative Medicine

Centre for Commercialization of Regenerative Medicine , a Canadian not-for-profit organization funded by the Government of Canada`s Networks of Centres of Excellence program, the Province of Ontario, and leading academic and industry partners, supports the development of regenerative medicines and associated enabling technologies, with a specific focus on cell and gene therapy. CCRM aims to accelerate the translation of scientific discovery into marketable products for patients with specialized teams funding, and infrastructure. CCRM sources and evaluates intellectual property from around the globe, offers various consulting services, conducts development projects with partners, and establishes new companies built around strategic bundles of intellectual property. CCRM is the commercialization partner of the Ontario Institute for Regenerative Medicine and the University of Toronto`s Medicine by Design. CCRM is hosted by the University of Toronto and was launched in Toronto`s Discovery District on June 14, 2011.